Updates on Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in the Treatment of Renal Anemia

BACKGROUND: Anemia is a common complication of chronic kidney disease. The hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) is a new class of oral drugs for the treatment of renal anemia. SUMMARY: Clinical trials have consistently shown that HIF-PHIs can effectively increase hemoglobi...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jing, Haase, Volker H., Hao, Chuan-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9900466/
https://www.ncbi.nlm.nih.gov/pubmed/36756084
http://dx.doi.org/10.1159/000527835

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9900466/
https://www.ncbi.nlm.nih.gov/pubmed/36756084
http://dx.doi.org/10.1159/000527835

Ejemplares similares